Dose Finding Study to Treat High Phosphate Levels in the Blood.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.
Also called NCT02081534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 162 participants
- Sponsor
- Registry
-
NCT02081534
-
- Other papers using this trial's data
- The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Poland, Slovakia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02081534. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-09-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose Finding Study to Treat High Phosphate Levels in the Blood.
- Condition
- Hyperphosphatemia
- Intervention (Drug)
- AZD1722
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ardelyx
Record details
- Record id
cardio:ct-nct02081534- Content hash
7095bc7a01243d07278adbbbade029b00854a9b9980edb4d6fdb5b63a2c7a238